Anti-inflammatory peptides as promising therapeutics agent against inflammatory bowel diseases: A systematic review

Abstract

Abstract Background Inflammatory bowel disease (IBD) is still an idiopathic condition; however, is probably associated to the dysregulation of gut mucosal immunity, intestinal microbiota dysbiosis, and environmental risk factors. Therefore, need call for novel therapeutic strategies. We aim to systematically review the latest current evidence on anti-inflammatory peptides (AIPs) as a new treatment approach in IBD, particularly by focus on Ulcerative Colitis and Cron’s diseases. Methodology: This systematic study was carried out in February 2023 following PRISMA 2020 guideline. Published studies that investigate the use of anti-inflammatory peptides for IBD treatment in were retrieved through searches of the literature in the Medline, Web of Science, and Cochrane databases. Results Seventeen studies satisfied the predesigned criteria and were involved, in which 12 of them used animal models of IBD, 4 were clinical trials, and one study was case-control. Results showed that H-SN1, a peptide derived from the snake’s venom and glucagon-like peptide-2 dimer (GLP-2②), significantly inhibits TNF cytotoxicity. Moreover, oral administration of AVX-470 (bovine-derived, anti-TNF antibody) reduced TNF, MPO, and apoptosis levels in enterocytes. Maintaining gut hemostasis and reversing gut dysbiosis could be effective in IBD treatment which Ac2-26 (a peptide that mimics annexin A1) and a combination of the αs2-casein peptide with synbiotics were helpful in this condition. AMP-18 (gastrokine-1) and MBCP (peptide derived from buffalo milk) can aid in preserving the intestinal barrier’s integrity by stabilizing tight junctions (TJs). This could potentially prevent IBD from occurring. Conclusion AIPs help reduce inflammation, regulate gut microbiota, and stabilize the intestinal barrier. However, their effectiveness can be limited due to destruction by proteases or harm to host cells. Further research should focus on improving their pharmacokinetic characteristics for better therapeutic potential.